Mechanisms of Action: How Each Peptide Works Tesamorelin Mimics GHRH Stimulates pulsatile GH release from the anterior pituitary Targets visceral adipose tissue, promoting lipolysis Increases IGF-1, improving metabolic health Ipamorelin Mimics ghrelin Binds GHS-R1a receptors Controlled GH release without cortisol/prolactin spikes Promotes slow, steady fat loss and muscle preservation Dosage and Administration General Guidelines Subcutaneous injections with 2831 gauge insulin syringes Administer 23 hours before sleep for GH peak Rotate sites and maintain sterile technique Tesamorelin 2mg (2000mcg) daily into the abdomen Continuous daily use for 26 weeks IGF-1 monitored every 26 weeks Ipamorelin 200300mcg per injection, 13 times daily Typical: 200mcg twice daily or 300mcg once before bed Cycles of 1216 weeks with 4-week breaks recommended Safety, Side Effects, and Long-Term Considerations Tesamorelin Injection site reactions (17%) Joint/muscle pain (1215%) Antibody formation may reduce effectiveness (~50%) Can worsen glucose tolerance, contraindicated in pregnancy or active cancer Ipamorelin Mild injection site irritation, occasional headaches Minimal disruption of natural hormones Well-tolerated long-term with low discontinuation rates Peptide Therapy for Men vs Women Metabolism and hormonal balance differ between sexes, influencing peptide results: Men Higher baseline GH and testosterone Tesamorelin may rapidly reduce visceral fat Ipamorelin helps maintain lean mass Women Lower GH and testosterone Tesamorelin can still target visceral fat effectively Ipamorelin is ideal for gradual fat loss and anti-aging purposes Lifestyle Integration: Nutrition, Exercise, and Recovery Peptides work best in combination with healthy lifestyle habits : Nutrition High-protein, moderate-carb diet supports muscle preservation Avoid processed sugars to reduce visceral fat Exercise Strength training enhances lean muscle gains High-intensity interval training (HIIT) accelerates fat loss Sleep and Recovery GH peaks during early sleep cycles
S.BarohnR
Preclinical studies using COPD mouse models revealed that GLP-1RA therapy significantly improved lung function and reduced both morbidity and mortality
How much will be the obesity GLP-1 market growth between 2025 and 2035
IUBMB Life 69 (6), 423434
